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Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder for which there is no current therapy preventing cumulative neuronal
loss. There is substantial evidence that mitochondrial dysfunction, oxidative stress, and associated caspase activity underlie the neurodegeneration
observed. One potential drug therapy is the potent free radical scavenger and antioxidant cystamine, which has demonstrated significant clinical
potential in models of neurodegenerative disorders and human neurological disease. This study examined the oral efficacy of cystamine in the
MPTP and 6-hydroxydopamine neurotoxin models of PD. The neuroprotective effects of cystamine treatment significantly ameliorated nigral
neuronal loss, preserved striatal dopaminergic projections, and improved striatal dopamine and metabolite levels, as compared to MPTP alone.
Cystamine normalized striatal 8-hydroxy-2′-deoxyguanosine levels and ATP concentrations, consistent with reduced oxidative stress and
improved mitochondrial function. Cystamine also protected against MPTP-induced mitochondrial loss, as identified by mitochondrial heat shock
protein 70 and superoxide dismutase 2, with concomitant reductions in cytochrome c and caspase-3 activities. The neuroprotective value of
cystamine was confirmed in the 6-hydroxydopamine model. Together these findings show cystamine's therapeutic benefit to reduce neuronal loss
through attenuation of oxidative stress and mitochondrial dysfunction, providing the rationale for human clinical trials in PD patients.
Published by Elsevier B.V.Keywords: Cystamine; MPTP; 6-OHDA; Basal ganglia; ATP; Capsase-3; Dopamine1. Introduction
Parkinson's disease (PD) is a devastating neurological dis-
order characterized by motor and behavioral disturbances re-
sulting from selective neurodegenerationwithin the basal ganglia.
PD affects approximately 2% of the population with incidence
variation associated with age, gender, and race [1–3]. It is the
second most common age-related neurodegenerative disorder⁎ Corresponding author. GRECCUnit 182B, Bedford VAMedical Center, 200
Springs Road, Bedford, MA 01730, USA. Tel.: +1 781 687 2908; fax: +1 781
687 3515.
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doi:10.1016/j.bbadis.2007.12.006after Alzheimer's disease. Clinical manifestations of PD initially
present as motor abnormalities, consisting of a resting tremor,
postural instability, and bradykinesia [4]. As disease progresses,
these motor symptoms worsen, with concurrent behavioral and
cognitive disruptions, including depression, anxiety, akinesia,
and ultimately dementia [5]. The neuropathology of idiopathic
PD is distinguished by a significant loss of dopaminergic neurons
within the substantia nigra pars compacta (SNpc) [6]. Loss of
dopaminergic nigral neurons is coincident with a decrease in
dopamine, the dopamine transporter (DAT), and the dopamine
metabolites dihydroxyphenylacetic acid (DOPAC) and homo-
vanillic acid (HVA) in PD brain [7–9].
Mitochondrial dysfunction and oxidative stress are widely
held to play pivotal roles in the observed neurodegeneration in
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human PD [10–12]. There is significant oxidative damage to
lipids, proteins, and DNA observed in postmortem PD stria-
tum and within the substantia nigra, along with decreased
glutathione levels [13–19]. In addition to reduced brain ATP
levels, mitochondrial alterations in peripheral tissue and post-
mortem PD brain are a major source of reactive oxygen
species [20–23]. Studies of 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP), which produces parkinsonism in
humans, and MPTP and rotenone toxicity in laboratory ani-
mals, show that the selective nigral neurodegeneration acts
through inhibition of complex I of the electron transport chain.
In addition, the neurotoxin 6-hydroxydopamine (6-OHDA)
has also been used as an experimental animal model of
parkinsonism to induce selective dopaminergic neuronal loss
in the substantia nigra. Consistent with the human PD
findings, toxin models in both non-human primates and mice
recapitulate the biochemical and cellular changes observed in
human PD [24–26], with a loss of dopaminergic nigral neu-
rons and dopamine, DAT, DOPAC, and HVA levels, along
with significant increases in reactive oxygen species [25,27–
30]. It is of great interest to note that substantia nigra dopa-
minergic neurons accrue mtDNA deletions with normal aging,
resulting in neuronal death [31,32].
Mitochondrial injury also activates apoptotic signaling path-
ways that result in neuronal death [33,34]. The release of cyto-
chrome c results in the activation of a family of cysteine
proteases known as caspases [35]. Cytochrome c activation of
caspase-9 induces the subsequent activation of caspase-3, the
downstream executioner molecule of this death signaling cas-
cade, resulting in both destruction of the intracellular architec-
ture as well as activating additional signaling cascades that
contribute to neuronal death [36]. Support for the role of cyto-
chrome c-mediated neuronal death in PD has been reported in
both PD patients and murine models of PD [37,38].
Existing medical care for PD primarily focuses on symptom
management, optimizing functions that are in continual decline,
and providing ever-increasing levels of assistance. Given the
lack of an effective therapeutic intervention that can halt or slow
the progression of PD, compounds with antioxidant capacities
and the ability to reduce mitochondrial dysfunction may be
efficacious. Among several promising compounds is cystamine,
a potent antioxidant, free radical scavenger, and caspase inhi-
bitor [39–41]. Cystamine has demonstrated significant neuro-
protection in multiple models of neurodegenerative disease
[42–46] and its reduced form, cysteamine, is safe, tolerable, and
effective in human diseases [47,48]. While the efficacy of
cystamine administration has previously been reported in the
MPTPmodel of parkinsonism [45], mechanisms of neuroprotec-
tion for cystaminewere not addressed. In addition, the doses used
in the above study were inconsistent with those previously
reported in other models of neurodegeneration. As such, the
present studies sought to determine a dose-dependent therapeutic
benefit with respect to neuronal loss and other neuropathological
sequelae along with how cystamine may ameliorate the patho-
physiological events associated with MPTP- and 6-OHDA-
induced neurodegeneration.2. Materials and methods
2.1. Animals
Male wild type mice with the B6CBA background were obtained from
Jackson Laboratories (Bar Harbor, ME) and maintained at the Bedford Veterans
AffairsMedical Center. A total of 135mice were used in theMPTP and 6-OHDA
studies. All mice were held in a temperature-controlled room that was maintained
under a 12-hour light/dark cycle and had access to food and water ad libitum. All
animal experiments were performed in accordance with the NIH Guide for the
Care and Use of Laboratory Animals and were approved by the Boston Univer-
sity School of Medicine and Veterans Administration Animal Care Committees.
2.2. MPTP and cystamine treatment
Adult mice (N=15/group) were randomly distributed into one of six treat-
ment groups at 8.5 months of age: untreated (no cystamine and no MPTP),
MPTP-treated (no cystamine), 120 mg/kg cystamine+MPTP, 250 mg/kg cysta-
mine+MPTP, 500 mg/kg cystamine+MPTP, or 750 mg/kg cystamine+MPTP.
Cystamine was prepared daily and administered in drinking water, with intake
monitored to maintain adequate dosing throughout the experiment. Using a
dosing strategy similar to previous neuroprotective studies in the MPTP model
of PD [49–51], all cystamine groups received cystamine treatment for one week
prior to MPTP administration. During the second week, cystamine treatment
continued and all MPTP treatment groups received intraperitoneal injections of
20 mg/kg MPTP b.i.d., over five days. Cystamine treatment continued for seven
days after the last MPTP treatment with mice euthanized at that time point for
biochemical and neuropathological analysis.
2.3. 6-OHDA and cystamine treatment
An additional cohort of mice were weighed and randomly placed into one of
three cystamine treatment groups at 8.5 months of age: untreated (no cystamine
and no 6-OHDA), 6-OHDA-treated (no cystamine), and 750 mg/kg cystamine+
6-OHDA (N=15/group). Cystamine was administered as noted above. After one
week of cystamine treatment, 6-OHDA (Sigma-Aldrich, USA) (2.5 μg) was
stereotactically injected into the right striatum (coordinates: 0.5 mm anterior to
bregma, −2.0 mm lateral to the midline, and 3.1 mm ventral) [52] under pento-
barbital anesthesia (50 mg/kg, i.p.). A Hamilton syringe was stereotactically
inserted and allowed to equilibrate for 30 s followed by injection over 60 s. Dwell
timewas 30 s. Cystamine administration continued for 1week after surgery.Mice
were then euthanized for neuropathological and biochemical analyses.
2.4. Histological evaluation
Mice (N=15/group) were deeply anesthetized and transcardially perfused
with 4%buffered paraformaldehyde at 90 days, with care to avoid the introduction
of any physical or perfusion artifact, post-fixed in the perfusate for 2 h, rinsed in
buffer and then cryoprotected in a graded series of 10 and 20% glycerol/2%
dimethyl sulfoxide. Frozen serial sections were cut at 50 μm, stored in six well
plates, and stained for Nissl substance using cresyl violet and for immunocyto-
chemical detection of tyrosine hydroxylase (TH), DAT, mitochondrial heat shock
protein 70 (mtHSP70), cytochrome c (cyt c), active caspase-3, or superoxide
dismutase 2 (SOD2). Sections were incubated overnight in mouse anti-TH
(1:2000; Chemicon, Temecula, CA), rabbit anti-DAT (1:500; Serotec, Raleigh,
NC), mouse anti-mtHSP70 (1:200; Affinity BioReagents, Golden, CO), rabbit
anti-cyt c (1:200; Santa Cruz, Santa Cruz, CA), anti-rabbit active caspase-3
(1:200; Abcam, Cambridge, MA), or anti-rabbit SOD2 (1:500, Abcam). Sections
were incubated in a goat anti-mouse or goat anti-rabbit peroxidase-conjugated
secondary antibody to detect TH and DAT and visualized using diaminobenzi-
dene. For immunofluorescent visualization, sections were incubated in donkey
anti-rabbit Cy3-congugated or donkey anti-mouse FITC-conjugated secondary
antibodies to detect mtHSP70, cyt c, active caspase-3, and SOD2 and counter-
stained with DAPI. An additional series of sections were processed for Fluoro-
Jade immunofluorescence (IF) (Histo-Chem Inc., Jefferson, AZ) staining as
previously described [53]. All immunofluorescent procedures were carried out in
the dark.
Fig. 1. Effect of cystamine onMPTP degradation and MPP+ formation. A. Brain
MPTP levels were not significantly altered in MPTP-treated brain compared to
MPTP–cystamine-treated brain. B. Similarly, levels of MPP+ were not signif-
icantly altered in MPTP-treated brain compared to MPTP–cystamine-treated
brain.
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Light and fluorescentmicroscopywas performed using aNikon Eclipse E800
microscope with a Spot RT digital camera. Digital imaging analysis of cyt c and
active caspase-3 puncta, representing apoptotic figures [54] was performed using
an IX81 microscope (Olympus, Inc.) equipped with a IX2-DSU3 spinning
confocal disk unit and a PLAPON 60XOTIRFM objective (NA 1.45; Olympus,
Inc.) and FL-CUBE dichromatic mirror and emission filter sets (Semrock).
Images were captured at 0.25 μm intervals, and stacks were deconvoluted with a
constrained iterative algorithm, using a cooled charge-coupled device camera
(Orca-ERGA; Hamamatsu). Optical sections and 3D images were captured using
IPLab (BD Biosciences, Bethesda, MD) and processed using Auto Deblur
(Media Cybernetics, Inc.). Rendered images were processed further for
Isosurface and 3 dimensional optics. The spatial distribution of MnSOD
(SOD2) in substantia nigral neurons was determined using confocal microscopy
and an image analysis program (Scanalytics BD Biosciences-Bioimaging and
AQI-X-COMBO-CWF, Media cybernetics Inc. Bethesda, MD). Isosurface
images were reconstructed after a deconvolution of the confocal image by the
AQI-X-COMBO-CWF program (Media cybernetics Inc. Bethesda, MD).
“Isosurfaces” are a graphical rendering technique that creates 2D contours in
3D space by interpolating between stacked sequential images, such as the 2D
cellular maps that comprise a cross section of the 3D data volume.We analyzed a
series of 40 confocal layers representing fluorescence data from substantia nigral
neurons and subsequently developed an abstract image that provided the results
seen in the Fig. 5.
2.6. Quantification/stereology
Absolute neuronal counts of Nissl and TH-immunoreactive (IR) neurons
were performed in the substantia nigra pars compacta (SNpc) from serial
sections throughout the rostro-caudal plane within the SNpc (from Interaural
0.88/bregma −2.92 through Interaural 0.00/bregma −3.80) [52]. To quantify cyt
c and caspase 3, immunofluorescence puncta representing apoptotic figures [54]
(N8 pixels) and SOD2 or mtHSP70 labeled mitochondria, rendered images from
the SNpc were analyzed using ImageJ and the ITCN module [55].
2.7. HPLC analysis
Identification of dopamine, DOPAC, and HVA in mouse brain was per-
formed as previously described [27]. To determine ATP levels, brain samples
were sonicated in cold (4 °C) perchloric acid and centrifuged. The supernatant
was neutralized with 2 M NaH2PO4, and samples were run on 16 channel
HPLC-EC Coularray (ESA, Chelmsford, MA) with 2 M NaH2PO4, 0.1%
methanol and 120 mg/L of tetrabutyl ammonium phosphate used for the A
mobile phase, and 0.1 M NaH2PO4, 0.1% methanol, 20% acetonitrile and
200 mg/L of tetrabutyl ammonium phosphate used for the B mobile phase. A
liquid chromatographic electrochemical carbon column switching technique
was employed for the detection of 8-hydroxy-2′-deoxyguanosine (8-OH2dG), as
previously described [56]. To determine MPTP and MPP+ levels, brain tissue
homogenates were incubated with either 10 μg MPTP/ml or 10 μg MPTP and
4 mg cystamine/ml. The samples were mixed and 100 μl were removed and
added to 400 μl of ice-cold acetonitrile/0.4% HAC. Samples of 100 μl were
removed for each time point (0 30, 60, and 120 min). Samples were centrifuged
and decanted, evaporated by speedvac and reconstituted in 100 μl mobile phase
A (0.1 M LiPO4 pH 2.9), and run on a 16 channel HPLC-EC Coularray (ESA,
Chelmsford, MA) with UV detection set at 240 nm and florescence set 210–310,
with a 40 min gradient. Buffers were mobile phase A and mobile phase B (0.1 M
LiPO4, 55% acetonitrile, pH 2.9). Both MPTP and MPP+ (Sigma-Aldrich) were
detected by UVand florescence using Shiseido C18 4.6×25 cm and Capcell pak
C18 4.6 mm×7.5 mm columns with the auto sampler set to 4 °C.
2.8. Statistics
Interval scale data involving more than two groups were analyzed using one-
way analysis of variance. If an overall significant difference was detected, multiple
comparisons were performed with Fishers least significant difference test. For the
MPTP conversion experiment, regression analyses were performed to determinewhether the slopes for the two conditions (MPTP vs. MPTP–cystamine) were
significantly different. For each analysis, we included MPTP or MPP+ levels as
the dependent variable, and three predictor variables: Minutes (0, 30, 60, 120),
Group (MPTP, MPTP–cystamine), and the interaction term Group×Minutes
expressed as a product vector (TheGroup×Minute vector inmultiple regression is
equivalent to a linear trend interaction component×group in ANOVA). For all
analyses, a significance level of p≤0.01 was observed.
3. Results
An analysis of MPTP conversion to MPP+ in the presence of
cystamine showed no differences between MPTP and MPTP–
cystamine treated brain homogenates (Fig. 1). Comparison of the
curves for MPTP levels in MPTP and MPTP–cystamine treated
brain using regression analysis (Fig. 1A) revealed no differences in
the rate of MPTP degradation (t(20)=0.197, p=0.846). Similarly,
comparison of the curves for MPP+ levels in MPTP- and MPTP–
cystamine-treated brain (Fig. 1B) revealed no differences in the
rate of MPP+ formation (t(20)=0.646, p=0.526). These results
provide evidence that cystamine does not disrupt MPTP
metabolism or the conversion of MPTP to MPP+.
Neuropathological examination of MPTP-treated mice re-
vealed bilateral lesions and a striking loss of Nissl-stained SNpc
neurons, as compared to untreatedmice (Fig. 2A and B; Table 1).
This was coincident with a conspicuous reduction in TH-IR
neurons and a marked increase in fluoro-jade-IF-positive
Table 1
Effects of cystamine on cell number within the substantia nigra in MPTP-treated
mice
Group Estimated cell count
Cresyl violet TH+
Untreated 951.2±6.64 ⁎ 711.8±13.05 ⁎
MPTP 473.8±9.35 † 261.0±20.17 †
MPTP+cystamine, 250 mg 693.5±5.32 # 394.5±2.87 #
MPTP+cystamine, 750 mg 896.6±3.44 ⁎⁎ 647.6±8.32 ⁎⁎
⁎pb0.0001 vs. all, †pb0.0001 vs. all, #p,0.0001 vs. all, ⁎⁎pb0.0001 vs. all.
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was observed using cystamine administration. Treatment with
cystamine (250 mg/kg) resulted in a decrease in SNpc neuronal
loss (Fig. 2C), along with improved numbers of TH-IR neurons
and a simultaneous decrease in fluoro-jade-IF-positive neurons.
Treatment with the highest dose of cystamine (750 mg/kg)
resulted in the greatest neuroprotection (Fig. 2D), combining a
relative sparing of TH-IR neurons with a near complete absence
of fluoro-jade-IF. Cell counts confirmed these observations
(Table 1). There was a significant reduction in the SNpc neuronal
number in Nissl-stained sections from MPTP-treated mice, as
compared to untreated mice (F(3,16)=881.04, pb0.01). A simi-
larly significant reduction in the number of TH-positive SNpc
neurons in MPTP-treated mice was also observed (F(3,15)=
311.6, pb0.01). Treatment with cystamine resulted in a dose-
dependent improvement in SNpc neuronal number. Cystamine
(250 mg/kg) significantly improved Nissl neuronal cell counts
and TH-positive neurons by 4.8% and 12.2%, respectively.Fig. 2. Neuroprotective effects of cystamine within the substantia nigra inMPTP-treate
(A), MPTP-treated mice (B), MPTP and 250 mg/kg cystamine (C), and MPTP and
(B) compared to non-lesioned mice (A). Pretreatment with 250 mg/kg cystamine (C) p
and significant neuroprotection is observed after pretreatmentwith 750mg/kg cystamin
immunoreactivity (TH-IR). There is a significant reduction in TH-IR after MPTP tre
250mg/kg cystamine significantly rescued neuronal TH-IR (C1), with greater improve
death using fluoro-jade-IF revealed no fluoro-jade-IF in untreated mice (A2). There
reduced in a dose-dependent manner by the administration of 250 mg/kg cystamine (Treatment with the highest dose of cystamine (750 mg/kg)
resulted in a significant (39%) improvement in Nissl SNpc
neuron cell numbers with a concomitant 84.8% neuroprotection
of TH-positive neurons compared to mice treated with MPTP
alone.
An analysis of striatal dopaminergic projections showed a
clear reduction in DAT-IR terminals in MPTP-treated micedmice. Cresyl violet staining of the substantia nigra in non-lesioned control mice
750 mg/kg cystamine (D) reveals marked neuronal loss in MPTP-treated mice
rovides significant protection against SNpc neuronal loss, while the most marked
e (D). Loss of dopaminergic neuronswas confirmed through tyrosine hydroxylase
atment (B1), as compared to non-lesioned control mice (A1). Pretreatment with
ment after administration of 750mg/kg cystamine (D1). Confirmation of neuronal
was a marked increase in fluoro-jade-IF in MPTP-treated mice (B2), which was
B3) and 750 mg/kg cystamine (D2). Bar in D = 200 μm.
Fig. 3. Neuroprotection of striatal dopaminergic projections after cystamine
administration in MPTP-treated mice. A. DAT-IR within the striatum in non-
lesioned control mice. B. Treatment with MPTP resulted in a marked reduction
of DAT-IR. C. Pretreatment with cystamine (750 mg/kg) ameliorated striatal
DAT-IR loss in MPTP-treated mice. Bar in C = 1 mm.
Fig. 4. The effect of cystamine administration on the levels of brain dopamine
and dopamine metabolites in MPTP-treated mice. A. MPTP treatment resulted
in a significant decrease in striatal dopamine levels compared with non-lesioned
control mice. Cystamine administration (750 mg/kg) significantly improved
striatal dopamine levels compared with MPTP-treated mice. B. Consistent with
an MPTP-mediated reduction in striatal dopamine, there was a significant
reduction in striatal DOPAC. Cystamine improved striatal DOPAC to levels
indistinguishable from untreated mice. C. MPTP treatment significantly reduced
HVA within the striatum, as compared to non-lesioned mice. Cystamine ad-
ministration significantly improved striatal HVA to comparable levels in non-
lesioned mice. ⁎pb0.01 vs. Untreated, MPTP–cystamine; #pb0.05 vs. Un-
treated, MPTP.
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Treatment with the highest dose of cystamine (750 mg/kg)
resulted in a marked improvement in DAT-IR terminal fibers in
the striatum. An analysis of striatal levels of dopamine, DOPAC
and HVA (Fig. 4) showed that levels of dopamine (F(2,22)=
33.19, pb0.01), DOPAC (F(2,21)=31.73, pb0.01), and HVA
(F(2,22)=20.78, pb0.01) were all significantly reduced inMPTP-
treated mice compared to untreated controls, and that cystamine
treatment significantly improved striatal levels of dopamine,
DOPAC and HVA.To assess mitochondria, the select mitochondrial markers
mtHSP70 and SOD2 were employed. Mitochondrial HSP70 is a
resident mitochondrial protein involved in protein translocation,
while SOD2 is a select marker of mitochondria that is an essential
component of the mitochondrial defense against oxidative dam-
age by reactive oxygen species. Loss in mitochondrial number
has not been previously reported inMPTP toxicity. In comparison
to untreated mice, MPTP treatment resulted in a significant re-
duction in mitochondrial number in SNpc neurons, as identified
Fig. 5. Cystamine reduced mitochondrial loss in the SNpc of MPTP-treated mice. Examination of mtHSP70-IF within the SNpc of a non-lesioned control mouse
(A) reveals mitochondria (red puncta) and nuclei (DAPI: blue). There is a significant MPTP-induced decrease in mtHSP70-positive mitochondria within SNpc neurons
(B). Treatment with cystamine significantly improved mtHSP70-positive mitochondrial number in MPTP-treated mice (C). Cystamine also improves SOD2-positive
mitochondria in the SNpc of MPTP-treated mice. The profile of SOD2-positive mitochondria within the SNpc of a non-lesioned control mouse (D) reveals
mitochondria (red puncta) and nuclei (blue). There is a marked MPTP-induced decrease in SOD2-positive mitochondria within the SNpc (E). Cystamine treatment
markedly improved the integrity of neuronal mitochondria in MPTP-treated mice. Examination of SOD2-IF within the SNpc of a cystamine-treated mouse (F) reveals
increased numbers of mitochondria. In comparison to non-lesioned mice (G), confocal 3 dimensional isosurface analysis of SOD2-IF shows distinct MPTP-induced
SOD2-positive mitochondrial translocation tightly formed around the nucleus (arrows) (H), which is reduced after pretreatment with cystamine in MPTP-treated mice
(I). Bar in C = 15 μm. Bar in F = 20 μm. Bar in I = 10 μm.
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mine treatment significantly ameliorated mitochondrial loss in
MPTP-treated mice (pb0.01). These results were confirmed
using an antibody against SOD2 (Fig. 5D–F). There was a
marked reduction in SOD2-positive mitochondria in MPTP-
treated mice compared with non-lesioned controls (non-lesioned
control: 9.67±0.16/5 μm2; MPTP-treated: 6.12±0.57/5 μm2;
MPTP/cystamine-treated: 9.50±0.23/5 µm2; F(2,9) =9.341,
pb0.01), that was significantly improved by cystamine treatment
( pb0.001). The degree of mitochondrial preservation in
cystamine-treated mice was consistent with the observed
neuronal sparing. Further analysis of SOD2-IF-positive mito-
chondria, using a novel 3 dimensional confocal method, revealed
that themitochondria had tightly translocated around the nucleus,
and that this phenomenon was reduced by cystamine treatment.
(Fig. 5G–I).
Consistent with the observed mitochondrial alterations, con-
focal analysis of neurons from the SNpc showed a marked
MPTP-mediated increase in cyt c-IF, as compared to non-
lesioned mice (F(2,6)=90.973, pb0.01; Fig. 6). Treatment with
cystamine (750 mg/kg) resulted in a significant decrease in cyt
c-IF compared with MPTP alone ( pb0.01). Consonant with theMPTP-mediated increase in cyt c-IF, there was a concomitant
significant MPTP-mediated increase in caspase-3 activation
(F(2,9)=143.69, pb0.01; Fig. 6) that was significantly reduced
after treatment with cystamine (750 mg/kg) ( pb0.01).
Together, these results demonstrate an MPTP-induced mito-
chondrial injury and activation of apoptotic signaling cascades
within the substantia nigra.
Improved mitochondrial function was further demonstrated
in the analysis of ATP levels. Striatal ATP levels were signifi-
cantly reduced in MPTP-treated mice, as compared to non-
lesioned control mice (F(2,28)=55.93, pb0.01) (Fig. 7A), with
significantly improved ATP levels in cystamine-treated mice
(750 mg/kg), such that they were statistically indistinguishable
from control mice. These findings were coupled with an atten-
uation of oxidative damage (Fig. 7B). Biochemical examination
revealed significantly elevated levels of 8-OH2dG in the stria-
tum of MPTP-treated mice, compared to non-lesioned control
mice (F(2,12)=11.22, pb0.01), that were normalized by cysta-
mine administration.
In order to provide additional support for the neuroprotective
potential of cystamine, a series of unilateral intracerebral 6-OHDA
injections were performed. 6-OHDA injections into the right
Fig. 7. Cystamine treatment significantly improved oxidative stress and mito-
chondrial dysfunction in MPTP-treated mice. A. Brain ATP levels were sig-
nificantly reduced in MPTP-treated mice compared with non-lesioned mice.
Cystamine administration significantly improved striatal ATP levels in MPTP-
treated mice to levels observed in non-lesioned mice. B. In contrast, Striatal
8-OH2dG levels were significantly elevated in MPTP-treated mice compared to
non-lesioned controls. Cystamine treatment significantly reduced 8-OH2dG in
MPTP mice to levels indistinguishable from non-lesioned mice. ⁎pb0.001 vs.
non-lesioned, MPTP–cystamine.
Fig. 6. Cystamine administration preserved neuronmitochondrial integrity within the substantia nigra and reduced both cyt c release and caspase-3 activation inMPTP-
treated mice. The profile of cyt c within the SNpc of a non-lesioned control mouse reveals mitochondria (red) surrounding neuronal nuclei (DAPI; blue) (A). There is a
marked MPTP-induced increase in cyt c-IF within the substantia nigra compared to non-lesioned control mice (B). Cystamine treatment significantly improved the
integrity of neuronal mitochondria in MPTP-treated mice, by significantly reducing cyt c-IF (C). Quantitative analysis of mitochondrial cyt c-IF confirms the
histological findings (D). Cystamine administration significantly ameliorates active caspase-3-IF in MPTP-treated mice. Active caspase-3 in the substantia nigra of in
non-lesioned control mice reveals active caspase-3-IF (red) surrounding neuronal nuclei (blue) (E). There is amarkedMPTP-induced increase in active caspase-3within
the substantia nigra compared to untreated control mice (F). Treatment with cystamine significantly reduced caspase-3 activity within the substantia nigra in MPTP-
treated mice (G). Quantitative analysis of active caspase-3-IF demonstrates a significant increase in MPTP-treated mice (H). Cystamine administration signif-
icantly reduced caspase-3 activity in MPTP-treated mice. Bar in C = 15 μm. ⁎pb0.01 vs. non-lesioned and MPTP–Cystamine, †pb0.01 vs. non-lesioned and MPTP.
Bar in G = 25 μm. Bar in inset (G) = 10 μm ⁎pb0.01 vs. non-lesioned, MPTP–cystamine.
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within the substantia nigra alongwith a significant reduction in the
number of TH-positive SNpc neurons, in comparison to non-
lesionedmice (F(3,16)=273.4, pb0.01) (Fig. 8 and Table 2). Using
the optimal dose of cystamine (750 mg/kg), there was a marked
improvement in TH-positive neurons in the SNpc (pb0.01).
Consistent with these findings, DAT-IR terminals in the striatum,
measured using densitometric analyses, were markedly reduced
by 76% after 6-OHDA administration and rescued by cystamine
treatment (96% of control) (Fig. 8). There were significantly
elevated levels of 8-OH2dG in the striatum of 6-OHDA-treated
mice compared to non-lesioned control mice (F(2,10)=9.31, pb
0.01) (Table 2) that were normalized by cystamine administration
(750 mg/kg), consistent with the MPTP findings.
4. Discussion
Therapeutic strategies that target the pathophysiological
indices of neuronal death in PD hold significant promise in the
treatment of patients with this neurological disorder. We show
that treatment with cystamine exerts a dose-dependent ther-
apeutic benefit in the murine MPTP and 6-OHDA models of
PD, providing significant neuroprotection, while ameliorating
biomarkers of oxidative stress and improving mitochondrial
dysfunction and loss.
Mitochondrial dysfunction in idiopathic PD (Fig. 9) has been
demonstrated through a reduction in complex I activity in
substantia nigra homogenates from PD brain [23,57]. This re-
duction in complex I activity is associated with decreased im-
munoreactivity for complex I [58]. While the underlying causes
of reduced complex I activity in PD are not well understood,
alterations in mtDNA have been suggested [59], along with
Fig. 8. Effects of 6-OHDA on tyrosine hydroxylase and DAT-IR in cystamine-treated mice. Intrastriatal microinjection of 6-OHDA resulted in a marked reduction of
tyrosine hydroxylase immunoreactive-positive (TH-IR) neurons within the substantia nigra (B), as compared to non-lesioned control mice (A). Pretreatment with
cystamine ameliorated TH-IR neuronal loss within the substantia nigra (C). Similar results were observed with DAT-IR within the striatum in non-lesioned mice (D),
with a marked unilateral reduction of DAT-IR in 6-OHDA-treated mice (E). Pretreatment with cystamine markedly improved DAT-IR (F). Bar in C = 200 μm; F =
1 mm.
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Indeed, alterations in mtDNA in the form of deletion mutations,
as well as damage resulting from oxidative stress, have been
observed in PD brain [19,32]. The mitochondrial genome en-
codes several RNA species, as well as 13 essential genes of the
respiratory chain, including complex I [62]. In addition, deficits
in complex I activity in PD platelets are associated with in-
creased production of free radicals [63].
Whether oxidative stress contributes to mitochondrial injury
or results as a consequence of mitochondrial dysfunction is notTable 2
Effects of cystamine on substantia nigra cell number and 8-OH2dG activity in
6-OHDA-treated mice
Group TH+ cell count 8-OH2dG level
Untreated controls 715.1±12.9 57.3±8.1 pg/μg
6-OHDA-treated 251.7±36.2⁎ 114.7±15.2 pg/μg⁎
6-OHDA+cystamine, 750 mg 609.3±17.4 68.9±11.3 pg/μg
⁎pb0.01 vs. all.well established. It is well understood, however, that mitochon-
dria, through oxidative phosphorylation and the electron
transport chain, produce free radicals, such as peroxynitrite
and the hydroxy radical [10,64]. Though an effective SOD2
scavenger system is present within normal mitochondria,
damaged mitochondria may be less effective in combating free
radical production, contributing to an increase in oxidative stress
(Fig. 9). We show a significant numeral reduction of mito-
chondria in MPTP-treated mice that may indeed be dysfunc-
tional, resulting in oxidative damage. Cystamine administration
ameliorates this mitochondrial loss and decreases 8-OH2dG, a
biomarker of oxidative damage. It is also of interest to note that
theMPTP-induced nuclear localization of SOD2 activity may be
a consequence of both nuclear fragmentation and loss of mito-
chondrial integrity.
Within the SNpc, there is also another prominent cascade
potentially responsible for the increase in oxidative stress ob-
served in PD. Dopamine metabolism by monoamine oxidase
results in the formation of hydrogen peroxide [13], and has been
Fig. 9. Mitochondrial Dysfunction in PD. Both MPTP and 6-OHDA promote oxidative stress and mitochondrial dysfunction, which are linked in a feed-forward
mechanism, increasing reactive oxygen species and the release of mitochondrial contents resulting in signaling cascades that promote neuronal death. Cystamine
reduces oxidative stress and improves mitochondrial function. This results in normalized mitochondria, ATP, and cyt c levels, as well as reduced activity of caspase-3,
improving neuronal viability.
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[65]. In the presence of iron, which is elevated in PD substantia
nigra [14], peroxide is catalyzed and oxygen radicals are formed
[66]. With the formation of reactive oxygen species, oxidative
damage to proteins, lipids, and DNA results. Importantly, once
oxidative damage occurs, it can promote additional oxidative
injury [64].
In addition, apoptosis and caspase activity have been impli-
cated in the neurodegeneration of PD [34]. Release of cyt c from
mitochondria ultimately results in the activation of caspase-3,
which executes cell death [33]. Importantly, increased caspase-
3-IR has been demonstrated in both human PD and the MPTP
murine model [37]. While the present series of experiments
cannot rule out a direct effect of cystamine on caspase-3-induced
neurodegeneration, previous work has demonstrated the ability
of cystamine to inhibit capsase-3 activity in vitro [40]. It is
important to note, however, that cystamine significantly reduced
the MPTP-induced increase in cyt c-IF. Given that caspase-3 is a
downstream target of cyt c, it is likely that cystamine-mediated
improvement in mitochondrial function prevents the release of
cyt c and the subsequent activation of caspase-3.
Altered protein–protein interactions leading to the formation
of proteinaceous cytoplasmic aggregates, termed Lewy bodies,
have also been suggested to play a role in PD pathogenesis [67].
A primary constituent of Lewy body inclusions is the protein
α-synuclein, mutations of which are associated with an auto-
somal dominant form of PD [68]. Recent evidence suggests that
α-synuclein aggregation is mediated in part by the activity of
tissue transglutaminase, which results in cross linkedα-synuclein
[69,70]. Cystamine, in addition to possessing antioxidant and
anti-caspase properties, is also a significant inhibitor of tissue
transglutaminase. Acute MPTP administration is not associated
with the formation of Lewy bodies in mice [71], and while the
present study did not asses α-synuclein-IR, therapeutic benefitthrough inhibition of tissue transglutaminase cannot be ruled
out, especially in light of recent findings demonstrating nigro-
striatal neuroprotection in transglutaminase 2 knock-out mice
treated with MPTP [72]. It is of importance to note that cross
linking of α-synuclein has also been shown to occur via oxi-
dative stress [73,74]. Thus, through antioxidant mechanisms,
anti-caspase activity, and transglutaminase inhibition, cystamine
has the potential to limit α-synuclein aggregation and thus
promote neuroprotection in PD.
Mouse toxin models replicate many, but not all of the clini-
cal, neuropathological, and molecular events observed in PD
and, as such, their relevance to the human condition has been
questioned. Postmortem PD tissues, however, only provide a
static window of pathology at end stage disease and do not
provide much understanding and characterization of early and
moderate neurodegenerative events. As a consequence, the uti-
lity of toxin models cannot be underestimated. Given aspects of
faithful disease recapitulation, toxin models that have been used
over the past 20 years have provided a significant literature in
identifying potential mechanisms of pathogenesis in the human
condition and the molecular basis of select dopaminergic neu-
ronal loss. Indeed, it has been shown that MPTP is a complex I
inhibitor of the mitochondrial electron transport chain and that
MPTP results in PD-like effects in humans [75–80]. The MPTP
model also supports a role for oxidative stress and mitochon-
drial dysfunction in PD. Once metabolized, MPTP is converted
to MPP+, which inhibits complex I. Inhibition of complex I
results in increased oxidative stress [81,82]. There is also a
decreased production of ATP in MPTP-treated mice, consistent
with perturbed oxidative phosphorylation observed in human
PD [23]. Oxidative stress and metabolic dysfunction are found
in both human PD and MPTP models of PD [10,12,62]. As
such, murine models that recapitulate human PD, such as
MPTP, provide a useful platform to assess therapeutic potential.
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drial dysfunction in PD, cystamine is a very attractive candidate
for therapeutic intervention. The long-term use of cysteamine
bitartrate (Cystagon®, Mylan Laboratories, Inc.), the reduced
form of cystamine and an orphan drug available in the US by
prescription, has been well documented, with a starting dose of
10 mg/kg/day and increased weekly until a target dose of
60– 90mg/kg/day is reached. Side effects are restricted to nausea
and vomiting. However, allergic rash, seizures and neutropenia
have occurred in rare cases as a result of not incrementally
increasing the dose [83]. These adverse events all resolve when
the drug is withdrawn. A Phase I study using cysteamine in HD
patients showed the drug to be safe and tolerable [47]. Previous
studies assessing the therapeutic benefit of the antioxidant
coenzyme Q10 in the MPTP model have demonstrated a signi-
ficant neuroprotective potential [84]. This has lead to clinical
trials of coenzyme Q10 in PD that have demonstrated therapeutic
efficacy [85,86]. The antioxidant creatine has also showed
significant neuroprotective potential in the MPTP model of PD
[87], which led to a successful clinical futility trial in PD [88].
While previous work with cystamine in the MPTP model has
been reported [45], no indication of the therapeutic neuroprotec-
tive mechanism was identified. In addition, this latter study
employed cystamine doses that were markedly lower than ef-
fective doses employed in previous neurodegenerative contexts
[43,44,46]. The doses of cystamine employed in the current study
closely resemble those dosages found previously to be
neuroprotective in other model systems. In addition, while the
route of administration differs between the two studies (oral vs.
intraperitoneal), it is worth noting previous work has demon-
strated the significant therapeutic potential of oral cystamine in
other murine models of neurodegeneration [89].
Importantly, while successful preclinical trials can demon-
strate improved phenotype in murine models of PD, validating
these results in PD patients is complicated by dose extrapola-
tions between mouse and man. The reliance on Human Equi-
valent Dose extrapolation measurements derived from body
surface area criteria in animals may not accurately predict the
maximum-recommended safe dose in humans [90]. Evidence in
support of this comes from human trials where human equivalent
dosing of bioenergetic agents based on preclinical murine trials
have not demonstrated similar efficacy in patients. The strengths
of mouse models are in their utility to provide parallel patho-
physiological targets that are present in patients, in their potential
as sensitive predictors for therapeutic intervention, and their
promise in the development of drug agents. While drug trials in
mice confirm therapeutic direction, the challenge is in deter-
mining what dose might be of value in patients since the phar-
macokinetics of mice and man is dissimilar. Notwithstanding, in
concert with preclinical animal studies and human safety and
tolerability trials in HD [47], the present findings provide the
rationale for initiating clinical safety and tolerability trials in
patients with PD using cystamine.
Acknowledgement
This work was supported by the Bumpus Foundation.References
[1] F.D. Dick, A. Seaton, N. Haites, S.E. Semple, S. Dick, G.J. Prescott, N.W.
Scott, J.E. Bennett, C.E. Counsell, A. Mutti, G. De Palma, P. Mozzoni, P.
Soderkvist, A. Ahmadi, M. Otelea, A. Felice, S. Bezzina Wettinger, En-
vironmental risk factors for Parkinson's disease and parkinsonism: the
Geoparkinson study, Occup. Environ. Med. 64 (2007) 666–672.
[2] A. Elbaz, J.H. Bower, D.M. Maraganore, S.K. McDonnell, B.J. Peterson,
J.E. Ahlskog, D.J. Schaid, W.A. Rocca, Risk tables for parkinsonism and
Parkinson's disease, J. Clin. Epidemiol. 55 (2002) 25–31.
[3] S.K.VanDenEeden,C.M. Tanner,A.L.Bernstein, R.D. Fross,A. Leimpeter,
D.A. Bloch, L.M.Nelson, Incidence of Parkinson's disease: variation by age,
gender, and race/ethnicity, Am. J. Epidemiol. 157 (2003) 1015–1022.
[4] S. Fahn, Description of Parkinson's disease as a clinical syndrome, Ann.
N.Y. Acad. Sci. 991 (2003) 1–14.
[5] E.C. Wolters, Intrinsic and extrinsic psychosis in Parkinson's disease,
J. Neurol. 248 (2001) 11122–11127.
[6] J. Fearnley, A.J. Lees, Parkinson'sDisease: pathology, in: R.Watts,W.Koller
(Eds.), Movement Disorders, McGraw-Hill, New York, 1997, pp. 263–278.
[7] B. Lach, D. Grimes, B. Benoit, A. Minkiewicz-Janda, Caudate nucleus
pathology in Parkinson's disease: ultrastructural and biochemical findings
in biopsy material, Acta Neuropathol. (Berl) 83 (1992) 352–360.
[8] G.W. Miller, J.K. Staley, C.J. Heilman, J.T. Perez, D.C. Mash, D.B. Rye,
A.I. Levey, Immunochemical analysis of dopamine transporter protein in
Parkinson's disease, Ann. Neurol. 41 (1997) 530–539.
[9] G.F. Wooten, Neurochemistry and neuropharmacology of Parkinson's dis-
ease, in: R. Watts, W. Koller (Eds.), Movement Disorders, McGraw-Hill,
New York, 1997, pp. 153–160.
[10] M.F. Beal, Mitochondria, oxidative damage, and inflammation in Parkin-
son's disease, Ann. N.Y. Acad. Sci. 991 (2003) 120–131.
[11] M.F. Beal, Mitochondria take center stage in aging and neurodegeneration,
Ann. Neurol. 58 (2005) 495–505.
[12] M.T. Lin, M.F. Beal, Mitochondrial dysfunction and oxidative stress in
neurodegenerative diseases, Nature 443 (2006) 787–795.
[13] Z.I. Alam, A. Jenner, S.E. Daniel, A.J. Lees, N. Cairns, C.D. Marsden, P.
Jenner, B. Halliwell, Oxidative DNA damage in the parkinsonian brain: an
apparent selective increase in 8-hydroxyguanine levels in substantia nigra,
J. Neurochem. 69 (1997) 1196–1203.
[14] D. Dexter, C. Carter, F. Wells, F. Javoy-Agid, Y. Agid, A. Lees, P. Jenner,
Basal lipid peroxidation in substantia nigra is increased in Parkinson's
disease, J. Neurochem. 52 (1989) 381–389.
[15] D.Dexter,A.Holley,W. Flitter, T. Slater, F.Wells, S.Daniel,A. Lees, P. Jenner,
C. Marsden, Increased levels of lipid hydroperoxides in the parkinsonian
substantia nigra: an HPLC and ESR study, Mov. Disord. 9 (1994) 92–97.
[16] T.L. Perry, V.W. Yong, Idiopathic Parkinson's disease, progressive sup-
ranuclear palsy and glutathione metabolism in the substantia nigra of
patients, Neurosci. Lett. 67 (1986) 269–274.
[17] J. Sanchez-Ramos, E. Overvik, B. Ames, A marker of oxyradical-mediated
DNA damage (8-hydroxy-2′deoxyguanosine) is increased in the nigro-
striatum of Parkinson's disease brain, Neurodegeneration 3 (1994) 197–204.
[18] E. Sofic, K.W. Lange, K. Jellinger, P. Riederer, Reduced and oxidized
glutathione in the substantia nigra of patients with Parkinson's disease,
Neurosci. Lett. 142 (1992) 128–130.
[19] J. Zhang, G. Perry, M.A. Smith, D. Robertson, S.J. Olson, D.G. Graham,
T.J. Montine, Parkinson's disease is associated with oxidative damage to
cytoplasmic DNA and RNA in substantia nigra neurons, Am. J. Pathol.
154 (1999) 1423–1429.
[20] R.H. Haas, F. Nasirian, K. Nakano, D. Ward, M. Pay, R. Hill, C.W. Shults,
Low platelet mitochondrial complex I and complex II/III activity in early
untreated Parkinson's disease, Ann. Neurol. 37 (1995) 714–722.
[21] M.T. Hu, S.D. Taylor-Robinson, K.R. Chaudhuri, J.D. Bell, C. Labbe, V.J.
Cunningham, M.J. Koepp, A. Hammers, R.G. Morris, N. Turjanski, D.J.
Brooks, Cortical dysfunction in non-demented Parkinson's disease patients: a
combined (31)P-MRS and (18)FDG-PET study, Brain 123 (2000) 340–352.
[22] B. Janetzky, S. Hauck, M.B. Youdim, P. Riederer, K. Jellinger, F. Pantucek,
R. Zochling, K.W. Boissl, H. Reichmann, Unaltered aconitase activity, but
decreased complex I activity in substantia nigra pars compacta of patients
with Parkinson's disease, Neurosci. Lett. 169 (1994) 126–128.
161E.C. Stack et al. / Biochimica et Biophysica Acta 1782 (2008) 151–162[23] A.H. Schapira, J.M. Cooper, D. Dexter, P. Jenner, J.B. Clark, C.D.Marsden,
Mitochondrial complex I deficiency in Parkinson's disease, Lancet 1 (1989)
1269.
[24] E. Brouillet, P. Hantraye, R.J. Ferrante, R. Dolan, A. Leroy-Willig, N.W.
Kowall, M.F. Beal, Chronic mitochondrial energy impairment produces
selective striatal degeneration and abnormal choreiform movements in
primates, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7105–7109.
[25] R.J. Ferrante, P. Hantraye, E. Brouillet, M.F. Beal, Increased nitrotyrosine
immunoreactivity in substantia nigra neurons in MPTP treated baboons is
blocked by inhibition of neuronal nitric oxide synthase, Brain Res. 823
(1999) 177–182.
[26] M. Varastet, D. Riche, M. Maziere, P. Hantraye, Chronic MPTP treatment
reproduces in baboons the differential vulnerability of mesencephalic do-
paminergic neurons observed in Parkinson's disease, Neuroscience 63
(1994) 47–56.
[27] O.A. Andreassen, R.J. Ferrante, A. Dedeoglu, D.W. Albers, P. Klivenyi,
E.J. Carlson, C.J. Epstein, M.F. Beal, Mice with a partial deficiency of
manganese superoxide dismutase show increased vulnerability to the mito-
chondrial toxins malonate, 3-nitropropionic acid, and MPTP, Exp. Neurol.
167 (2001) 189–195.
[28] P. Klivenyi, O.A. Andreassen, R.J. Ferrante, A. Dedeoglu, G. Mueller, E.
Lancelot, M. Bogdanov, J.K. Andersen, D. Jiang, M.F. Beal, Mice defi-
cient in cellular glutathione peroxidase show increased vulnerability to
malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahy-
dropyridine, J. Neurosci. 20 (2000) 1–7.
[29] Z.L. Rossetti, A. Sotgiu, D.E. Sharp, M. Hadjiconstantinou, N.H. Neff,
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals
in vitro, Biochem. Pharmacol. 37 (1988) 4573–4574.
[30] R.J. Smeyne, V. Jackson-Lewis, The MPTP model of Parkinson's disease,
Brain Res. Mol. Brain Res. 134 (2005) 57–66.
[31] M.F. Beal, Bioenergetic approaches for neuroprotection in Parkinson's
disease, Ann. Neurol. 53 (2003) 39–47.
[32] A. Bender, K.J. Krishnan, C.M. Morris, G.A. Taylor, A.K. Reeve, R.H.
Perry, E. Jaros, J.S. Hersheson, J. Betts, T. Klopstock, R.W. Taylor, D.M.
Turnbull, High levels of mitochondrial DNA deletions in substantia nigra
neurons in aging and Parkinson's disease, Nat. Genet. 38 (2006) 515–517.
[33] R.M. Friedlander, Apoptosis and caspases in neurodegenerative diseases,
N. Engl. J. Med. 348 (2003) 1365–1375.
[34] W.G. Tatton, R. Chalmers-Redman, D. Brown, N. Tatton, Apoptosis in
Parkinson's disease: signals for neuronal degradation, Ann. Neurol. 53
(2003) 61–70.
[35] E.S. Alnemri, D.J. Livingston, D.W. Nicholson, G. Salvesen, N.A. Thorn-
berry, W.W. Wong, J. Yuan, Human ICE/CED-3 protease nomenclature,
Cell 87 (1996) 171.
[36] M. Enari, H. Sakahira, H. Yokoyama, K. Okawa, A. Iwamatsu, S. Nagata,
A caspase-activated DNase that degrades DNA during apoptosis, and its
inhibitor ICAD, Nature 391 (1998) 43–50.
[37] A. Hartmann, S. Hunot, P.P. Michel, M.P. Muriel, S. Vyas, B.A. Faucheux,
A. Mouatt-Prigent, H. Turmel, A. Srinivasan, M. Ruberg, G.I. Evan, Y.
Agid, E.C. Hirsch, Caspase-3: A vulnerability factor and final effector in
apoptotic death of dopaminergic neurons in Parkinson's disease, Proc.
Natl. Acad. Sci. U. S. A. 97 (2000) 2875–2880.
[38] V. Viswanath, Y. Wu, R. Boonplueang, S. Chen, F.F. Stevenson, F. Yantiri,
L. Yang, M.F. Beal, J.K. Andersen, Caspase-9 activation results in down-
stream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,
6-tetrahydropyridine-induced Parkinson's disease, J. Neurosci. 21 (2001)
9519–9528.
[39] V. Gentile, A.J. Cooper, Transglutaminases — possible drug targets in
human diseases, Curr. Drug Targets CNSNeurol. Disord. 3 (2004) 99–104.
[40] M. Lesort, M. Lee, J. Tucholski, G.V. Johnson, Cystamine inhibits caspase
activity. Implications for the treatment of polyglutamine disorders, J. Biol.
Chem. 278 (2003) 3825–3830.
[41] L. Revesz, H. Modig, Cysteamine-induced increase of cellular glutathione-
level: a new hypothesis of the radioprotective mechanism, Nature 207
(1965) 430–431.
[42] D.R. D'Souza, J. Wei, Q. Shao, M.D. Hebert, S.H. Subramony, P.J. Vig,
Tissue transglutaminase crosslinks ataxin-1: possible role in SCA1 patho-
genesis, Neurosci. Lett. 409 (2006) 5–9.[43] A. Dedeoglu, J.K. Kubilus, T.M. Jeitner, S.A. Matson, M. Bogdanov, N.W.
Kowall, W.R. Matson, A.J. Cooper, R.R. Ratan, M.F. Beal, S.M. Hersch,
R.J. Ferrante, Therapeutic effects of cystamine in a murine model of
Huntington's disease, J. Neurosci. 22 (2002) 8942–8950.
[44] M.V. Karpuj, M.W. Becher, J.E. Springer, D. Chabas, S. Youssef, R.
Pedotti, D. Mitchell, L. Steinman, Prolonged survival and decreased
abnormal movements in transgenic model of Huntington's disease, with
administration of the transglutaminase inhibitor cystamine, Nat. Med. 8
(2002) 143–149.
[45] M.E. Tremblay, M. Saint-Pierre, E. Bourhis, D. Levesque, C. Rouillard, F.
Cicchetti, Neuroprotective effects of cystamine in aged parkinsonian mice,
Neurobiol. Aging 27 (2006) 862–870.
[46] J.M. Van Raamsdonk, J. Pearson, C.D. Bailey, D.A. Rogers, G.V. Johnson,
M.R. Hayden, B.R. Leavitt, Cystamine treatment is neuroprotective in the
YAC128 mouse model of Huntington's disease, J. Neurochem. 95 (2005)
210–220.
[47] R. Dubinsky, C. Gray, CYTE-I-HD: phase I dose finding and tolerability
study of cysteamine (Cystagon) in Huntington's disease, Mov. Disord. 21
(2006) 530–533.
[48] W.A. Gahl, J.G. Thoene, J.A. Schneider, Cystinosis, N. Engl. J. Med. 347
(2002) 111–121.
[49] M. Dhanasekaran, S. Uthayathas, S.S. Karuppagounder, K. Paramesh-
waran, V. Suppiramaniam, M. Ebadi, H.M. Brown-Borg, Ebselen effects
on MPTP-induced neurotoxicity, Brain Res. 1118 (2006) 251–254.
[50] A. Kreisler, P. Gele, J.F. Wiart, M. Lhermitte, A. Destee, R. Bordet, Lipid-
lowering drugs in the MPTP mouse model of Parkinson's disease: feno-
fibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA
reductase inhibitors do not, Brain Res. 1135 (2007) 77–84.
[51] W. Zhang, E.J. Shin, T. Wang, P.H. Lee, H. Pang, M.B. Wie, W.K.
Kim, S.J. Kim, W.H. Huang, Y. Wang, W. Zhang, J.S. Hong, H.C. Kim,
3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigro-
striatal pathway against MPTP-elicited damage both in vivo and in vitro,
FASEB J. 20 (2006) 2496–2511.
[52] K. Franklin, G. Paxinos, The Mouse Brain in Stereotaxic Coordinates,
Academic Press, New York, 2000.
[53] L.C. Schmued, C. Albertson, W. Slikker Jr., Fluoro-Jade: a novel fluo-
rochrome for the sensitive and reliable histochemical localization of neu-
ronal degeneration, Brain Res. 751 (1997) 37–46.
[54] Z. Huang, Q. Hou, N.S. Cheung, Q.T. Li, Neuronal cell death caused by
inhibition of intracellular cholesterol trafficking is caspase dependent
and associated with activation of the mitochondrial apoptosis pathway,
J. Neurochem. 97 (2006) 280–291.
[55] W. Rasband, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/ 1997-
2006.
[56] M.B. Bogdanov, M.F. Beal, D.R. McCabe, R.M. Griffin, W.R. Matson, A
carbon column-based liquid chromatography electrochemical approach to
routine 8-hydroxy-2′-deoxyguanosine measurements in urine and other
biologicmatrices: a one-year evaluation of methods, Free Radic. Biol.Med.
27 (1999) 647–666.
[57] Y.Mizuno, S. Ohta, M. Tanaka, S. Takamiya, K. Suzuki, T. Sato, H. Oya, T.
Ozawa, Y. Kagawa, Deficiencies in complex I subunits of the respiratory
chain in Parkinson's disease, Biochem. Biophys. Res. Commun. 163 (1989)
1450–1455.
[58] N. Hattori,M. Tanaka, T. Ozawa, Y.Mizuno, Immunohistochemical studies
on complexes I, II, III, and IVof mitochondria in Parkinson's disease, Ann.
Neurol. 30 (1991) 563–571.
[59] S. Ikebe, M. Tanaka, K. Ohno, W. Sato, K. Hattori, T. Kondo, Y. Mizuno, T.
Ozawa, Increase of deletedmitochondrialDNA in the striatum in Parkinson's
disease and senescence, Biochem. Biophys. Res. Commun. 170 (1990)
1044–1048.
[60] N. Jha, O. Jurma, G. Lalli, Y. Liu, E.H. Pettus, J.T. Greenamyre, R.M. Liu,
H.J. Forman, J.K. Andersen, Glutathione depletion in PC12 results in
selective inhibition of mitochondrial complex I activity. Implications for
Parkinson's disease, J. Biol. Chem. 275 (2000) 26096–26101.
[61] P.M. Keeney, J. Xie, R.A. Capaldi, J.P. Bennett Jr., Parkinson's dis-
ease brain mitochondrial complex I has oxidatively damaged subunits
and is functionally impaired and misassembled, J. Neurosci. 26 (2006)
5256–5264.
162 E.C. Stack et al. / Biochimica et Biophysica Acta 1782 (2008) 151–162[62] A.H. Schapira, Mitochondrial involvement in Parkinson's disease, Hun-
tington's disease, hereditary spastic paraplegia and Friedreich's ataxia,
Biochim. Biophys. Acta 1410 (1999) 159–170.
[63] J.P. Sheehan, R.H. Swerdlow, W.D. Parker, S.W. Miller, R.E. Davis,
J.B. Tuttle, Altered calcium homeostasis in cells transformed by mito-
chondria from individuals with Parkinson's disease, J. Neurochem. 68
(1997) 1221–1233.
[64] H.H. Szeto, Mitochondria-targeted peptide antioxidants: novel neuropro-
tective agents, AAPS J. 8 (2006) 521–531.
[65] G. Cohen, Oxidative stress, mitochondrial respiration, and Parkinson's
disease, Ann. N.Y. Acad. Sci. 899 (2000) 112–120.
[66] J.D. Adams, I.N. Odunze, Oxygen free radicals and Parkinson's disease,
Free Radic. Biol. Med. 10 (1991) 161–169.
[67] P. Jenner, C. Olanow, Pathological evidence for oxidative stress in Parkin-
son's disease and related degenerative disorders, in: C. Olanow, P. Jenner,
M. Youdim (Eds.), Neurodegeneration and Neuroprotection in Parkinson's
Disease, Academic Press, London, 1998, pp. 24–46.
[68] M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, A.
Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E.S. Stenroos, S. Chan-
drasekharappa, A. Athanassiadou, T. Papapetropoulos, W.G. Johnson, A.M.
Lazzarini, R.C. Duvoisin, G. Di Iorio, L.I. Golbe, R.L. Nussbaum,Mutation
in the alpha-synuclein gene identified in families with Parkinson's disease,
Science 276 (1997) 2045–2047.
[69] G. Andringa, K.Y. Lam, M. Chegary, X. Wang, T.N. Chase, M.C. Bennett,
Tissue transglutaminase catalyzes the formation of alpha-synuclein cross-
links in Parkinson's disease, FASEB J. 18 (2004) 932–934.
[70] E. Junn, R.D. Ronchetti, M.M. Quezado, S.Y. Kim, M.M. Mouradian,
Tissue transglutaminase-induced aggregation of alpha-synuclein: im-
plications for Lewy body formation in Parkinson's disease and de-
mentia with Lewy bodies, Proc. Natl. Acad. Sci. U. S. A. 100 (2003)
2047–2052.
[71] M. Orth, S.J. Tabrizi, Models of Parkinson's disease, Mov. Disord. 18
(2003) 729–737.
[72] G. Battaglia, M.G. Farrace, P.G. Mastroberardino, I. Viti, G.M. Fimia, J.
Van Beeumen, B. Devreese, G. Melino, G. Molinaro, C.L. Busceti, F.
Biagioni, F. Nicoletti, M. Piacentini, Transglutaminase 2 ablation leads to
defective function of mitochondrial respiratory complex I affecting neu-
ronal vulnerability in experimental models of extrapyramidal disorders,
J. Neurochem. 100 (2007) 36–49.
[73] H. Ischiropoulos, Oxidative modifications of alpha-synuclein, Ann. N.Y.
Acad. Sci. 991 (2003) 93–100.
[74] J.M. Souza, B.I. Giasson, Q. Chen, V.M. Lee, H. Ischiropoulos, J. Biol.
Chem. 275 (2000) 18344–18349.
[75] M.F. Beal, Experimental models of Parkinson's disease, Nat. Rev. Neurosci.
2 (2001) 325–334.
[76] R. Betarbet, T.B. Sherer, G.MacKenzie,M. Garcia-Osuna, A.V. Panov, J.T.
Greenamyre, Chronic systemic pesticide exposure reproduces features of
Parkinson's disease, Nat. Neurosci. 3 (2000) 1301–1306.[77] M. Gerlach, P. Riederer, Animal models of Parkinson's disease: an empi-
rical comparison with the phenomenology of the disease in man, J. Neural
Transm. 103 (1996) 987–1041.
[78] I.J. Kopin, MPTP: an industrial chemical and contaminant of illicit nar-
cotics stimulates a new era in research on Parkinson's disease, Environ.
Health Perspect. 75 (1987) 45–51.
[79] J.W. Langston, P. Ballard, J.W. Tetrud, I. Irwin, Chronic Parkinsonism in
humans due to a product of meperidine-analog synthesis, Science 219
(1983) 979–980.
[80] M. Sedelis, K. Hofele, G.W. Auburger, S. Morgan, J.P. Huston, R.K.
Schwarting, MPTP susceptibility in the mouse: behavioral, neurochemical,
and histological analysis of gender and strain differences, Behav. Genet. 30
(2000) 171–182.
[81] M. Cleeter, J. Cooper, A. Schapira, Irreversible inhibition of mitochondrial
complex I by 1-methyl-4-phenylpyridinium: evidence for free radical in-
volvement, J. Neurochem. 58 (1992) 786–789.
[82] K. Sriram, K.S. Pai, M.R. Boyd, V. Ravindranath, Evidence for generation
of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice,
Brain Res. 749 (1997) 44–52.
[83] B.J. Corden, J.D. Schulman, J.A. Schneider, J.G. Thoene, Adverse reac-
tions to oral cysteamine use in nephropathic cystinosis, Dev. Pharmacol.
Ther. 3 (1981) 25–30.
[84] M.F. Beal, R.T. Matthews, A. Tieleman, C.W. Shults, Coenzyme Q10
attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced
loss of striatal dopamine and dopaminergic axons in aged mice, Brain Res.
783 (1998) 109–114.
[85] The NINDSNet-PD Investigators, A randomized clinical trial of coenzyme
Q10 and GPI-1485 in early Parkinson's disease, Neurology 68 (2007)
20–28.
[86] C.W. Shults, D. Oakes, K. Kieburtz, M.F. Beal, R. Haas, S. Plumb, J.L.
Juncos, J. Nutt, I. Shoulson, J. Carter, K. Kompoliti, J.S. Perlmutter, S.
Reich, M. Stern, R.L. Watts, R. Kurlan, E. Molho, M. Harrison, M. Lew,
Effects of coenzyme Q10 in early Parkinson's disease: evidence of slowing
of the functional decline, Arch. Neurol. 59 (2002) 1541–1550.
[87] R.T.Matthews, R.J. Ferrante, P. Klivenyi, L. Yang, A.M. Klein, G.Mueller,
R. Kaddurah-Daouk, M.F. Beal, Creatine and cyclocreatine attenuate
MPTP neurotoxicity, Exp. Neurol. 157 (1999) 142–149.
[88] The NINDS Net-PD Investigators, A randomized, double-blind, futility
clinical trial of creatine and minocycline in early Parkinson's disease,
Neurology 66 (2006) 664–671.
[89] A. Dedeoglu, J.K. Kubilus, L. Yang, K.L. Ferrante, S.M.Hersch,M.F. Beal,
R.J. Ferrante, Creatine therapy provides neuroprotection after onset of
clinical symptoms in Huntington's disease transgenic mice, J. Neurochem.
85 (2003) 1359–1367.
[90] Federal Drug Administration, Guidance for Industry and Reviewers
Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in
Adult Healthy Volunteers, 2003 Washington, DC, http://www.fda.gov/
cber/guidelines.htm/.
